Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764510 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ADRD2TDP1 | |
| SCHEMBL3758399 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ADRD2TDP1 | |
| SCHEMBL13052234 | 0.80 | KMT2A (0.43) | MEN1GAAKMT2ADRD2TDP1 | |
| SCHEMBL3823663 | 0.80 | CCR5 (0.36) | TDP1ALDH1A1 | |
| SCHEMBL2683841 | 0.78 | MEN1 (0.57) | MEN1GAAKMT2ADRD2TDP1 | |
| SCHEMBL21214308 | 0.77 | DRD2 (0.55) | DRD2TDP1L3MBTL1ALDH1A1GFER | |
| SCHEMBL16502104 | 0.75 | TDP1 (0.42) | MEN1GAAKMT2ADRD2TDP1 | |
| SCHEMBL16426501 | 0.74 | CA1 (0.38) | GAAKMT2AL3MBTL1 | |
| SCHEMBL3758163 | 0.73 | EPHX1 (0.46) | MEN1GAAKMT2ADRD2EPHX1 | |
| SCHEMBL397759 | 0.72 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | MEN1 4855/4885GAA 4390/4885KMT2A 4728/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | MEN1 4855/4885GAA 4390/4885KMT2A 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.